Despite the efficacy of imatinib in GIST with imatinib-sensitive activating KIT mutations, tyrosine kinase inhibitors have been disappointing in small cell carcinoma of the lung (SCCL) [31], [32], [33], 28-88% of which are reported to be KIT+ [17]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.